Vaccine Efficacy Against SARS-CoV-2, 14 Days After the Second and Third Doses in Cohort 1 and Cohort 2 Among the Vaccine and Placebo Groups
death
ASYMPTOMATIC COVID-19, SECONDARY
Confirmed symptomatic COVID-19 indicates the primary outcome, and severe cases as the secondary outcome; only 1 COVID-19–related death was observed in the placebo group during the follow-up period in cohort 1.Vaccine efficacy was defined as a 1 – The spike gene sequencing analysis of 419 participants with RT-PCR–positive testing revealed that the Alpha variant was dominant before June 10, 2021 (when the second dose was administered). However, 1 month after the second dose, Delta became the dominant variant as of August 2021 when 100% of individuals with positive RT-PCR testing were infected with the Delta variant (eFigure 4 in Consistent with other vaccine trials,